Skip to main content
Fig. 3 | BMC Rheumatology

Fig. 3

From: Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry

Fig. 3

Cost-effectiveness plane of the comparison of initial combination therapy with step-up therapy. Results of probabilistic sensitivity analysis. Five hundred patients are displayed. X-axis: incremental effects (in Quality-Adjusted Life Years). Y-axis: Incremental costs (in €‘s). 64% of trials are in the southeast quadrant, and thus cost-saving. 87% of trials are cost-effective at a Willingness-to-Pay threshold of €60,000

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us